<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We investigated efficacy and safety of rabbit anti-thymocyte globulin (rATG), <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> and granulocyte colony-stimulating factor (G-CSF) as first-line therapy for patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) and low or intermediate-1 or hypoplastic <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>rATG 3.5 mg/kg (or 2.5 mg/kg per day for patients &gt;or=55 years with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) was given for 5 days </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="4031">Cyclosporine</z:chebi> (5 mg/kg) and G-CSF (5 microg/kg) were given daily and continued for up to 6 months or longer </plain></SENT>
<SENT sid="3" pm="."><plain>Responses were assessed about 3 and 6 months after therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Thirty-six patients have been enrolled on study and 32 patients treated; 25 were evaluable for a response (13 with AA, 12 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>); the rest are too early </plain></SENT>
<SENT sid="5" pm="."><plain>The median age was 62 years (range, 20-83) for patients with AA and 63 (range, 42-80) for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Of 13 patients, 12 (92%) patients with AA responded (5 complete response (CR), 7 partial response (PR)), whereas of 12 patients, 4 (33%) patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> responded (1 CR, 3 PR) </plain></SENT>
<SENT sid="7" pm="."><plain>For patients with AA, the median time to response (TTR) was 93 days (range, 79-623), whereas in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> group the median TTR was 111 days (range, 77-139) </plain></SENT>
<SENT sid="8" pm="."><plain>Grade III/IV toxicities were mainly cytopenias and neutropenic <z:hpo ids='HP_0001945'>fever</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Combination of rATG, <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> and G-CSF is safe and effective as first-line treatment of AA and has significant activity in low-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>